Back to search results

DAREON®-Lung-1: Obrixtamig for Advanced Small Cell Lung Cancer

This study is for adults with advanced small cell lung cancer (SCLC). It's testing if adding obrixtamig to standard treatment (atezolizumab, carboplatin, and etoposide) helps people live longer compared to standard treatment alone. Obrixtamig is a molecule that may help your immune system fight cancer. The study also aims to test a new medical device for measuring a tumor marker called DLL3. Participants are randomly assigned to receive either obrixtamig plus standard treatment or standard treatment alone. The main goal is to see if obrixtamig improves overall survival over 36 months. The study is currently unclear on its recruitment status and plans to enroll 670 people.

Study design
This is an interventional study with 670 planned participants, who will be randomly assigned to one of two treatment groups.
What's involved
You would be in the study for up to 3 years, receiving all treatments as infusions into a vein.
Compensation
Not stated in the trial record.
Follow-up
Overall survival will be measured for up to 36 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07472517

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

Recruiting
PHASE3Ages 18+InterventionalTreatment
Boehringer Ingelheim
~670 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:obrixtamigatezolizumabcarboplatinetoposide

At a glance

Recruiting sites
110 of 245 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall survival (OS)
Measured over Up to 36 months

Conditions

Small Cell Lung Cancer (SCLC)
Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Explore related trials

Lung Small Cell Carcinoma

Where it's being run

245 sites across 56 states
China33
Spain17
Germany14
Japan12
Turkey (Türkiye)11
France10
Italy10
South Korea10

Who to contact

Boehringer Ingelheim
[email protected]
1-800-243-0127
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Treatment for brain metastases (e.g. whole brain radiation therapy, stereotactic radiotherapy, or radiosurgery) completed at least 7 days prior to randomisation and the patient is neurologically stable without the use of glucocorticoids or therapeutic anti-convulsant for at least 7 days prior to randomisation
Untreated brain metastases that do not require treatment and the patient is neurologically stable without the use of glucocorticoids or therapeutic anti-convulsant for at least 28 days prior to randomisation 5. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 6. Eligible for continuing carboplatin + etoposide + atezolizumab regimen as first-line Standard of care (SoC) treatment within 28 days after the start of the initial cycle of standard therapy

What this trial measures

  • Overall survival (OS)Up to 36 months

    OS, defined as the time from randomisation until death from any cause